Patent for GeneQuine’s Lead Products Granted by European Patent Office

A patent for GeneQuine’s lead products was granted by the European Patent Office, which represents a major milestone in securing intellectual protection in the target markets.

The patent covers helper-dependent adenoviral vectors expressing interleukin-1 receptor antagonist and their use in the treatment of osteoarthritis in several species including humans, horses and dogs. Several other corresponding national patent applications are currently being processed worldwide.